Skip to main content

MED

Columbus Community Hospital Receives Spravato treatment certification

Nov 05, 2021 03:07PM ● By Med Magazine

Columbus Community Hospital received its certification to become an Outpatient Spravato Treatment Center. Spravato is a nasal spray prescription medication used in combination with an oral anti-depressant. It treats major depressive symptoms in adults who have tried other anti-depressant medicines, but have not benefited from them (treatment-resistant depression).  

The nasal spray treatment will be dispensed by the hospital pharmacy and seclf-administered by the patient in the hospital’s infusion center. “It’s important for people to know that depression and treatment for depression are common,” said Dr. Venkata Kolli, physician with the Columbus Psychiatry Clinic. “Spravato is a safe treatment, and we’re making it safer through our collaboration with the hospital’s infusion center.”

Now that CCH has received the certification to become an Outpatient Spravato Treatment Center, the next step will be for the hospital’s infusion center, pharmacy, and outpatient clinic providers and staff to participate in a comprehensive training program prior to the targeted December 2021 opening. The specialized training and protocol development will allow the team to safely and effectively administer the medication and monitor patients, resulting in an excellent patient experience and the best patient outcomes. 

“Here at CCH, we work together to improve the lives of others by utilizing all available treatment options,” said Korie Whitmore, director of clinics with Columbus Community Hospital. “This breakthrough treatment allows us to redefine how we treat major depression, giving patients and their families hope for improvement and symptom relief.”

For more information regarding the Columbus Psychiatry Clinic, visit our website at www.columbushosp.org.